antibody

Synaptobrevin 2 antibody (clone 3E5)

MBS200052

0.05 mL

240 USD

monoclonal

mouse

nonconjugated

3.00E+05

human, rat

western blot, ELISA, enzyme immunoassay

Antibody

Synaptobrevin 2 antibody (clone 3E5)

Synaptobrevin 2

VAMP2; SYB2; Synaptobrevin 2; VAMP-2; Synaptobrevin-2; Vesicle-associated membrane protein 2; vesicle-associated membrane protein 2 FLJ11460; RATVAMPB; RATVAMPIR; SYB; VAMP 2; Vesicle associated membrane protein 2; Vesicle-associated membrane protein 2 (synaptobrevin 2).

vesicle-associated membrane protein 2; Vesicle-associated membrane protein 2; vesicle-associated membrane protein 2; synaptobrevin 2; synaptobrevin-2; vesicle associated membrane protein 2; vesicle-associated membrane protein 2 (synaptobrevin 2); Synaptobrevin-2

VAMP2; VAMP2; SYB2; VAMP-2; SYB2; VAMP-2

VAMP2_HUMAN

Monoclonal

IgG1, k

3.00E+05

Mouse

Human, Rat

116

By protein-G affinity chromatography

Liquid. Supplied in Phosphate-Buffered Saline (pH 7.4) with 0.1% Sodium Azide.

1mg/ml

Can be stored at 4 degree C. For long term storage, aliquot and store at -20 degree C. Avoid repeated freezing and thawing cycles.

ELISA (EIA), Western Blot (WB) (Recombinant protein,Cell lysate)

The antibody has been tested by ELISA and Western blot analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results. Recommended dilution range for Western blot analysis is 1:1,000 ~ 3,000. Recommended starting dilution is 1:2,000.

Antigen Species: Human. Clone: Anti-human Synaptobrevin 2 mAb, clone 3E5, is derived from hybridization of mouse SP2/O myeloma cells with spleen cells from BALB/c mice immunized with a recombinant human Synaptobrevin 2 protein. Immunogen: Recombinant human Synaptobrevin 2 (1-89aa) purified from E Coli

Neuroscience

Synaptobrevin 2(Vesicle-associated membrane, VAMP2), which is an 18 kDa integral membrane protein localized to the cytoplasmic surface of synaptic vesicle, consists of a proline-rich N-terminal region, a highly conserved hydrophilic domain, followed by a transmembrane anchor and a C-terminal tail. Synaptobrevin 2 is predominantly expressed in Langerhans islets and glomerular cells. The N-terminal domain of the protein forms a specific SNARE complex with the target membrane-associated t- or Q-SNAREs syntaxin 1 and SNAP-25. This antibody recognizes specifically synaptobrevin 2, but it also shows a low affinity to synaptobrevin 1.

Andres C et al.,(1995) Proc Natl Acad Sci USA 92:5987-5991 Jacobsson G et al.,(1998) European Journal of Neuroscience 16:301-316 Scales SJ. et al (2002) J Biol. Chem. 227(31):28271-28279 Pennuto M et al., (2003) Mol Biol Cell. 14:4909-19

172072620

NP_055047

NM_014232.2

12,663 Da

Acetylcholine Neurotransmitter Release Cycle Pathway (106525); Clathrin Derived Vesicle Budding Pathway (119545); Disease Pathway (530764); Dopamine Neurotransmitter Release Cycle Pathway (106523); Effects Of Botulinum Toxin Pathway (138028); GABA Synthesis, Release, Reuptake And Degradation Pathway (187174); Glutamate Neurotransmitter Release Cycle Pathway (106522); Golgi Associated Vesicle Biogenesis Pathway (119546); Insulin Signaling Pathway (198845); Insulin Processing Pathway (105903)

The protein encoded by this gene is a member of the vesicle-associated membrane protein (VAMP)/synaptobrevin family. Synaptobrevins/VAMPs, syntaxins, and the 25-kD synaptosomal-associated protein SNAP25 are the main components of a protein complex involved in the docking and/or fusion of synaptic vesicles with the presynaptic membrane. This gene is thought to participate in neurotransmitter release at a step between docking and fusion. The protein forms a stable complex with syntaxin, synaptosomal-associated protein, 25 kD, and synaptotagmin. It also forms a distinct complex with synaptophysin. It is a likely candidate gene for familial infantile myasthenia (FIMG) because of its map location and because it encodes a synaptic vesicle protein of the type that has been implicated in the pathogenesis of FIMG. [provided by RefSeq, Jul 2008]

VAMP2: a member of the vesicle-associated membrane protein (VAMP)/synaptobrevin family. Synaptobrevins/VAMPs, syntaxins, and the 25-kD synaptosomal-associated protein SNAP25 are the main components of a protein complex involved in the docking and/or fusion of synaptic vesicles with the presynaptic membrane. Thought to participate in neurotransmitter release at a step between docking and fusion. The protein forms a stable complex with syntaxin, synaptosomal-associated protein, 25 kD, and synaptotagmin. It also forms a distinct complex with synaptophysin. Protein type: Vesicle; Motility/polarity/chemotaxis; Membrane protein, integral. Chromosomal Location of Human Ortholog: 17p13.1. Cellular Component: zymogen granule membrane; neuron projection; intracellular membrane-bound organelle; synaptic vesicle membrane; clathrin-coated vesicle; secretory granule membrane; integral to plasma membrane; trans-Golgi network; cytosol; secretory granule; SNARE complex; synaptic vesicle; membrane; perinuclear region of cytoplasm; plasma membrane; synapse; cytoplasmic vesicle; cell junction. Molecular Function: calmodulin binding; SNAP receptor activity; SNARE binding; protein binding; protein self-association; syntaxin binding; syntaxin-1 binding; phospholipid binding; calcium-dependent protein binding. Biological Process: exocytosis; natural killer cell degranulation; neurotransmitter secretion; neutrophil degranulation; pathogenesis; calcium ion-dependent exocytosis; vesicle-mediated transport; regulation of exocytosis; vesicle fusion; synaptic transmission; protein transport; synaptic vesicle exocytosis; cellular protein metabolic process; cellular response to insulin stimulus; glutamate secretion; Golgi to plasma membrane protein transport; energy reserve metabolic process; response to glucose stimulus; eosinophil degranulation; protein complex assembly; post-Golgi vesicle-mediated transport; regulation of insulin secretion

0.05 mL

240 USD

0.1 mL

315